2020
DOI: 10.18773/austprescr.2020.021
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: Proteinuria, in particular albuminuria, is a potentially significant modifiable risk factor for cardiovascular disease and the progression of kidney disease. Current treatment guidelines for albuminuria recommend a single renin-angiotensin-aldosterone inhibitor. This can be an ACE inhibitor or an angiotensin receptor antagonist. The routine use of combined renin-angiotensin-aldosterone inhibition for albuminuria is not supported by current evidence. Combination therapy is associated with higher rates of advers… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
3
0

Year Published

2022
2022
2023
2023

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(3 citation statements)
references
References 34 publications
0
3
0
Order By: Relevance
“…ACE inhibitors therapy significantly reduces the tendency of proteinuria and postpones the decline in renal function. 10,11 It will slow down the progression of chronic kidney disease in the presence or absence of diabetes, particularly in patients with mild to moderate renal insufficiency. 12,13 This patient complained of 12 kg weight loss in one month.…”
Section: Discussionmentioning
confidence: 99%
“…ACE inhibitors therapy significantly reduces the tendency of proteinuria and postpones the decline in renal function. 10,11 It will slow down the progression of chronic kidney disease in the presence or absence of diabetes, particularly in patients with mild to moderate renal insufficiency. 12,13 This patient complained of 12 kg weight loss in one month.…”
Section: Discussionmentioning
confidence: 99%
“…We also investigated if candesartan (angiotensin II-receptor blocker), losartan (angiotensin II-receptor blocker), dapagliflozin (sodium/glucose cotransporter 2 (SGLT2) inhibitor) or enalaprilat (angiotensin-converting enzyme (ACE) inhibitor) could counteract the effects of TMAO on megalin expression. These drugs are currently extensively used against proteinuria in patients [ 45 ]. We found that candesartan, dapagliflozin and enalaprilat, but not losartan, counteracted the suppressive effect of TMAO on megalin expression.…”
Section: Discussionmentioning
confidence: 99%
“…Diabetes is the leading cause of chronic kidney disease, frequently resulting in albuminuria [ 60 ]. Renin-angiotensin-aldosterone inhibition, through either an ACE inhibitor or angiotensin receptor antagonist, is the current treatment guideline for albuminuria, and is reported to slow the progression of kidney disease [ 61 ]. Oxidative stress due to ROS may initiate the progression of vascular and endothelial dysfunction associated with type 2 diabetes [ 23 ].…”
Section: Overview Of Clinical Trialsmentioning
confidence: 99%